Oxford BioMedica in a £738.88m deal with Axovant which specialises in treatment for neurological diseases is a subsidiary of Roivant Sciences. Oxford BioMedica, one of Britain’s oldest biotech companies, has sealed an $842.5m ( £738.88m) deal with Axovant Sciences of the US to commercialise its gene therapy for Parkinson’s disease. New of the worldwide deal…
The Indian government imposed a ban on codeine-based Corex cough syrups, as they posed a health risk, and soon after shares in the Indian unit of US based drugmaker Pfizer tumbled by 9 per cent. Pfizer’s India unit said in a statement it had stopped selling its Corex cough syrup that contains codeine, a…
The Californian group, Porteus Digital health has developed the first “digital pill” that tell doctors when their patients have taken them – had its drug application accepted by US regulators. This chip in the pill will ensure patients stick to their prescriptions and reduce the wasteful spending on drugs that are not taken properly. This…